SEC Filing Summary: Athira Pharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Athira Pharma, Inc. (not Leonabio, Inc.) on March 24, 2022. The filing serves as a current report to announce the issuance of a press release detailing the Company's financial results for the fiscal year ended December 31, 2021. The Company is an emerging growth company incorporated in Delaware, with its common stock trading on the Nasdaq Global Select Market under the symbol ATHA.
Key Financial Metrics
The provided filing text acts as a cover document and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the press release furnished as Exhibit 99.1, which is not included in the input text.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text body. It solely references the publication of the full year 2021 results in the attached press release.
Guidance, Outlook, and Risks
Regulation FD Disclosure: The Company disclosed its channels for material information, including its website, investor relations portal, and social media accounts (Twitter, LinkedIn, Facebook). Investors are encouraged to monitor these channels for updates on product candidates and other material matters.
Unusual Items: None identified in the text provided.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the March 24, 2022 press release), as they are absent from this 8-K text.
- Confirm the Company's name is Athira Pharma, Inc., noting the discrepancy with the "Leonabio, Inc." label in the request metadata.
- Review the Company's social media channels and investor relations website for any subsequent updates on product candidates mentioned in the Regulation FD disclosure.
- Check the status of the Company's "Emerging Growth Company" election and any related accounting standard transitions.